Repligen Corporation

NASDAQ RGEN

Download Data

Repligen Corporation Price to Book Ratio (P/B) on June 03, 2024: 4.26

Repligen Corporation Price to Book Ratio (P/B) is 4.26 on June 03, 2024, a -80.19% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.
  • Repligen Corporation 52-week high Price to Book Ratio (P/B) is 25.06 on February 16, 2024, which is 487.84% above the current Price to Book Ratio (P/B).
  • Repligen Corporation 52-week low Price to Book Ratio (P/B) is 4.20 on May 30, 2024, which is -1.44% below the current Price to Book Ratio (P/B).
  • Repligen Corporation average Price to Book Ratio (P/B) for the last 52 weeks is 15.92.
NASDAQ: RGEN

Repligen Corporation

CEO Mr. Anthony J. Hunt
IPO Date March 26, 1990
Location United States
Headquarters Building 1, Waltham, MA, United States, 02453
Employees 1,783
Sector Healthcare
Industry Medical instruments & supplies
Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Similar companies

BDX

Becton Dickinson and Company

NA

NA

HOLX

Hologic Inc

NA

NA

ANGO

AngioDynamics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email